ABSTRACT
INTRODUCTION
Sex hormone binding globulin (SHBG) is the major binding protein for gonadal steroids in the circulation. [1] It was originally described as a hepatically secreted protein and thereby regulating the availability of free steroids to hormone-responsive tissues. [2] In women, increased androgenicity, as reß ected by low circulating SHBG concentrations, has been related to hyperinsulinemia, glucose intolerance, and insulin resistance, as well as to the risk of cardiovascular disease and type 2 diabetes. An androgenic sex steroid proÞ le as reß ected by low circulating SHBG is also associated with an increased accumulation of abdominal fat in women. [3] At present there is much evidence that insulin may be an important modulator of SHBG concentrations. In vitro, insulin is a potent inhibitor of SHBG production by HepG2 cells [4] and reduces the stimulatory effect of 17β-estradiol and thyroxine. [5] In vivo, reduced serum SHBG levels may indicate the presence of insulin resistance states with hyperinsulinemia, such as polycystic ovary syndrome [6] or obesity. [7] Furthermore, a recent prospective study identiÞ ed low levels of SHBG as a risk factor for future diabetes mellitus. [8] Thus, one may argue that low SHBG levels are associated with CHD by indicating the presence of the insulin resistance / hyperinsulinemia syndrome.
Previous studies have demonstrated that reduced plasma levels of SHBG are related to alterations in several features of the MetS in men and women. [9] [10] [11] [12] Most of the research linking low SHBG and high androgens to cardiovascular risk has been restricted to postmenopausal women. [13] [14] [15] The aim of this study was to determine SHBG concentrations in premenopausal women who were otherwise healthy, and to evaluate the relationships between SHBG concentrations and features of the MetS.
MATERIALS AND METHODS
Retrospective cross-sectional analysis was carried out on 350 obese and overweight patients aged 25 to 69 years referred to the Department of Endocrinology and Metabolic Diseases of Pamukkale University hospital in [2002] [2003] . Records are stored in folders in the institution and the same person retrieved all the data. We studied the Turkish population living in Denizli province of Aegean geographical region of Turkey. Our samples were from the inner part of the Aegean region of Turkey.
All of the patients were obese and overweight, BMI > 25kg/m 2 . Patients who were under treatment with contraceptive drugs or hormone replacement therapy (HRT), or diagnosed with polycystic ovary disease, thyroid disease, chronic renal failure, chronic hepatopathy or cancer, were excluded from the study. Presence of medical conditions was assessed through self-report. Thyroid status was assessed by freeT3 (fT3), freeT4 (fT4), and thyrotrophin (TSH) levels.
Insulin resistance was estimated by homeostatic model assessment ratio formula [HOMA-IR = (Fasting plasma insulin (µIU/mL) x fasting plasma glucose (mmol/L)) /22,5] . [16] Free androgen index (FAI) was used to estimate the amount of testosterone unbound by SHBG and thus, immediately biologically active. FAI was calculated as the ratio of testosterone (ng/ ml) to SHBG (ng/mL)x100. [3] The deÞ nition of menopausal status was in accordance with the following criteria: [17] -Women presenting normal menses or who in any case reported at least 10 cycles in the previous year and without climacteric-related symptoms, and having follicle stimulating hormone levels lower than 12.75 IU/l, were included in the premenopausal group. 125 premenopausal euthyroid patients were eligible for this study (mean age: 35.6 ± 9.35 Patients were divided into two groups according to the body mass index (BMI): Group I (overweight women), women with BMI < 30 kg/m 2 (n = 17) and Group II (obese women), women with BMI > or = 30 kg/m 2 (n = 108). The values of the SHBG concentrations were scattered and median SHBG concentrations were used. Median SHBG concentration of Group I was 50.1nmol/L. Group II (obese women) was divided into two subgroups according to the median SHBG concentration of Group I. Women with high SHBG levels (SHBG concentration > or = median level of the control group, i.e.> or =50.1nmol/L) (n = 26) and women with low SHBG levels (< 50.1 nmol/L) (n = 82).
Anthropometric measurements
Height and weight were measured in light clothing without shoes. Body height was measured by a statometer and body weight by digital electronic weighing scales. Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters. Waist circumferences were measured using a flexible measuring tape, midway between the xiphoid and the umbilicus during the midinspiratory phase, respectively. Anthropometric measurements were carried out three times by a single tester. Body water and fat distribution was assessed by multiple frequency bioelectric impedance measurement with a portable impedance analyzer (Tanita, Tokyo, JAPAN).
Blood pressure
The average of two measurements of blood pressure (BP) with the subject in the sitting position was taken at a 2 to 3 min interval after resting for at least 15 min.
Metabolic syndrome deÞ nition
The metabolic syndrome (MetS) was deÞ ned by an NIH Expert Panel (referred to as the ATPIII guidelines). [18] MetS was deÞ ned as presence of three or more of the following:
• Waist circumference (cm) >88 • Systolic BP > 130mm Hg or diastolic BP > 85 mmHg • HDL cholesterol <50mg/dL • Impaired fasting glucose (IFG), fasting plasma glucose>110mg/dL • Triglycerides > 150 mg/dL
Laboratory analyses
Serum levels of fasting and postprandial glucose, total cholesterol, triglyceride, HDLcholesterol, LDL-cholesterol and uric acid were analyzed with commercial kits (Beckman -Coulter, USA) in an autoanalyzer (Beckman -Coulter LX-20, USA) while the levels of serum insulin, fT3, fT4, TSH, testosterone, estradiol (E2), sex-hormone binding protein, FSH and LH were determined in an immunanalyzer (Immulite 2000, USA) using chemiluminescence method.
Statistical analyses
Descriptive statistics, proportions for categorical variables and means, median and standard deviations for continuous variables were used to describe the study groups. Comparisons between Group I and Group II were performed by Mann Whitney-U test. Comparisons between low SHBG and high SHBG groups were performed by Student's t test. The multivariant regression analysis was performed using backward method. Regression test was used to analyze the relationship between SHBG, body weight, BMI, waist circumference, fat percentage, fasting glucose, postprandial glucose, gamma glutamyl transferase (GGT) and free androgen index (FAI). All statistical analyses were performed using SPSS 9.0 software (SPSS Inc.).
P value less than 0.05 was considered as signiÞ cant.
RESULTS
The patient characteristics (means and S.E.M.) of the studied group and the measured parameters are shown in table 1.
Median SHBG concentration of Group I was 50.1 nmol/L (mean value was 64.28 nmol/L with a standard deviation of 50.27 nmol/L). The values of the SHBG concentrations were scattered, and median SHBG concentrations were used.
Characteristics and study parameters in women in Group I and Group II are shown in table 2. Subjects in Group I had lower BMI, with signiÞ cantly lower waist circumference, fat %, systolic and diastolic blood pressure, uric acid, and GGT level (P = 0.000, P = 0.000, P = 0.000, P = 0.000, P = 0.004, P = 0.003, P = 0.029). 
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HOMA values were significantly lower and SHBG concentrations were signiÞ cantly higher in this group as well (P = 0.025, P = 0.025).
Group II (our obese group) was divided into two subgroups according to the median SHBG concentration of the Group I. The obese women with SHBG concentrations > 50.1nmol/L were regarded as the group with high SHBG and women with SHBG concentrations < 50.1 nmol/L were regarded as the group with low SHBG.
The study parameters of the obese subgroups are shown in table 3.
No signiÞ cant difference was found in mean age between low and high SHBG group (P = 0.875).
The low SHBG group was significantly heavier, and had higher BMI, with higher waist circumference than high SHBG group (P = 0.032, P = 0.024, P = 0.004).
In the low SHBG group, fasting glucose, postprandial glucose, GGT and FAI levels was signiÞ cantly higher (P = 0.001, P = 0.005, P = 0.019, P = 0.031).
Similar lipid profile (TG, HDL cholesterol), blood pressure, uric acid, insulin and HOMA were found between two groups (P = 0.580, P = 0.138, P = 0.986, P = 0.781, P = 0.143, P = 0.869, P = 0.275).
Significant correlations of the SHBG with other study parameters using multiple linear regression analysis, with SHBG as the dependent variable are shown in table 4.
Linear regression analyses (backward) revealed that free androgen index (FAI) was a signiÞ cant SEX HORMONE BINDING GLOBULIN AND METABOLIC SYNDROME IN PREMENOPAUSAL WOMEN independent predictor of SHBG concentrations in premenopausal women (P = 0.012) [ Figure 1 ].
DISCUSSION
Whether SHBG is a causal agent of the MetS or merely represents a marker for primary endocrine abnormalities leading to these metabolic alterations remains unclear at the present time. We investigated the interactions of a variety of clinical and laboratory parameters characterizing the metabolic syndrome. We focused on premenopausal women, because most of the previous studies were on postmenopausal subjects.
Tchernof, Garaulet and coworkers performed similar studies in premenopausal women too. [3, 19] But the size of our study group was larger than Tchernof and Garaulet's groups. The biggest epidemiological study about SHBG and cardiovascular risk in multiethnic premenopausal and perimenopausal women is the SWAN (Study of Women Across the Nation) study. They reported that low SHBG and high FAI were strongly associated with CV risk factors even after controlling for BMI. [20] In our study FAI was used to estimate the amount of testosterone unbound by SHBG, thus biologically active like SWAN group. In the present study, obese women with low SHBG concentrations had signiÞ cantly higher FAI. The cause and effect relationships between SHBG concentrations and MetS components in obese women could not be assessed because of the cross sectional nature of our study.
Another big comprehensive study was performed by Hajamour et al. [12] Their data were obtained from Quebec Family Study (QFC). They reported that plasma SHBG level may represent a significant predictor of the MetS in men and premenopausal women. The association between plasma SHBG and variables of glucose homeostasis w e r e s i g n i f i c a n t i n p r e m e n o p a u s a l women. [7] Our results also conÞ rm their data. Our study shows strong relationships between SHBG and anthropometric measurements and fasting glucose, postprandial glucose, GGT levels and FAI in premenopausal women. Linear regression analyses (backward) revealed that BMI and FAI were significant independent predictors of SHBG concentrations in premenopausal women [ Figure 1 ].
The accelerated accretion of adipose tissue in the intra-abdominal region coincident with the onset of menopause may explain part of the increased risk of cardiovascular disease in postmenopausal women. [4] But premenopausal women showed gynoid type obesity, with a smaller abdominal perimeter. They were lowest in most abdominal fat distribution parameters. [19] In this study, we found that total or intra-abdominal obesity mediated an important part of the relation between low SHBG and an altered metabolic proÞ le by using BMI and waist circumference. The results of the present study are concordant with previous investigators. [3, [21] [22] [23] Our obese group showed upper body obesity, and had higher waist circumference and higher HOMA value than overweight subjects. Higher uric acid level and blood pressure was found as expected. Hyperuricemia is reported to be an inherent component of MetS and could be used as a simple marker for insulin resistance.
Low SHBG frequently coincides with components of MetS, such as low levels of HDL cholesterol and high levels of triglycerides and apolipoprotein B. [11, 24, 25] In this study, no signiÞ cant difference was found in mean insulin concentrations, HOMA index, blood pressure, triglycerides, HDL and uric acid between the low and high SHBG groups. Determinants of SHBG blood concentrations are likely to change on passing from premenopausal to postmenopausal status. [26] FAI is an important determinant of SHBG in both premenopausal and postmenopausal women as expected. Our finding also confirms these results. It is known that estrogens protect pancreatic β-cells from apoptosis and have insulinotrophic effects. [27] In postmenopausal status this effect is lost and insulin levels decrease. The positive effect of estradiol on SHBG levels is probably stronger in premenopausal women than in postmenopausal women. That is why SHBG didn't correlate insulin resistance and MetS component in premenopausal obese women.
In a recent study, it has been noted that after menopause, the impact of insulin resistance on SHBG level seems more important than estradiol. Therefore, it could be argued that SHBG level can be correlated with insulin resistance for postmenopausal women. [28] The major difÞ culty with our study is that values of the SHBG concentrations were scattered. The mean value was 64.2 nmol/L with SD of 50.3, therefore we used median SHBG concentration to show the signiÞ cance of the work. A similar study was designed by Cikim et al. [29] They studied 307 premenopausal women. They used median SHBG levels too. Their low SHBG group was signiÞ cantly younger, with higher waist-to-hip ratio (WHR). Triglycerides, uric acid, insulin and HOMA values were signiÞ cantly lower their low SHBG group. Their multivariant regression analyses showed age and uric acid concentrations in the whole group. They reported that low SHBG concentrations may indicate a severe degree of insulin resistance in premenopausal women. But in our study, no significant difference was found in mean age between low and high SHBG group. The low SHBG group was signiÞ cantly heavier and had higher BMI with higher waist circumference than high SHBG group. Although fasting glucose, postprandial glucose, GGT levels and FAI were signiÞ cantly higher in our low SHBG group, lipid proÞ le (TG, HDL cholesterol), blood pressure, uric acid, insulin and HOMA were found similar between the two groups.
In summary, according to our Þ ndings, SHBG levels didn't correlate with insulin resistance in premenopausal obese women. Linear regression analyses (backward) demonstrated that BMI and FAI were signiÞ cant independent predictors of SHBG concentrations in premenopausal obese women. It is concluded that low SHBG concentrations may indicate visceral obesity and glucose intolerance in premenopausal obese women.
